Hari A Deshpande1, Sanziana Roman, Julie A Sosa. 1. Department of Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut 06520, USA. Hari.deshpande@yale.edu
Abstract
PURPOSE OF REVIEW: Anaplastic thyroid cancer is the most aggressive solid tumor known to humans. Even when found in a localized form, the prognosis is grave. For metastatic disease, there has been little effect on survival using traditional chemotherapy. RECENT FINDINGS: Over a five-decade interval, there has been little progress in the treatment of this malignancy. However, targeted agents represent a new mode of treatment, and some studies have shown encouraging preclinical results. Combretastatin has shown activity in phase 1 and phase II trials; although the registration phase III study failed to meet its accrual goals, it did appear to show some benefit, especially in younger patients. SUMMARY: Combinations of this compound and other targeted agents may prove to be a breakthrough in an otherwise untreatable cancer.
PURPOSE OF REVIEW: Anaplastic thyroid cancer is the most aggressive solid tumor known to humans. Even when found in a localized form, the prognosis is grave. For metastatic disease, there has been little effect on survival using traditional chemotherapy. RECENT FINDINGS: Over a five-decade interval, there has been little progress in the treatment of this malignancy. However, targeted agents represent a new mode of treatment, and some studies have shown encouraging preclinical results. Combretastatin has shown activity in phase 1 and phase II trials; although the registration phase III study failed to meet its accrual goals, it did appear to show some benefit, especially in younger patients. SUMMARY: Combinations of this compound and other targeted agents may prove to be a breakthrough in an otherwise untreatable cancer.
Authors: Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen Journal: Oncologist Date: 2014-09-26
Authors: Keisuke Enomoto; Xuguang Zhu; Sunmi Park; Li Zhao; Yuelin J Zhu; Mark C Willingham; Jun Qi; John A Copland; Paul Meltzer; Sheue-Yann Cheng Journal: J Clin Endocrinol Metab Date: 2017-07-01 Impact factor: 5.958
Authors: Christina A von Roemeling; Laura A Marlow; Anthony B Pinkerton; Angela Crist; James Miller; Han W Tun; Robert C Smallridge; John A Copland Journal: J Clin Endocrinol Metab Date: 2015-02-12 Impact factor: 5.958